LakeShore Biopharma Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.
Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials.
The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
| Country | Cayman Islands |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 573 |
| CEO | Wang Xu |
Contact Details
Address: Building No. 2 Beijing, 102629 China | |
| Phone | 86 10 8920 2086 |
| Website | lakeshorebio.com |
Stock Details
| Ticker Symbol | LSBCF |
| Exchange | OTCMKTS |
| Fiscal Year | April - March |
| Reporting Currency | CNY |
| ISIN Number | KYG9845F2080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wang Xu | Chief Executive Officer and Director |
| Rui Yu M.B.A., M.S. | Chief Financial Officer and Director |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | President, Chief Business Officer and Vice Chairman |
| Zhiyuan Ran | Head of Marketing and Sales |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Dr. Honggang Teng | Head of Production and Quality Management |